Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) Bundle
Curious whether Shenzhen Salubris Pharmaceuticals (002294.SZ) is a growth story or an overvalued biotech? Dive into a focused breakdown: Q3 2025 revenue jumped to CNY 1.11 billion (+15.85% YoY) and TTM revenue hit CNY 4.25 billion (+8.76%), while Q3 net profit attributable rose to CNY 215.63 million (+30.19% YoY) with a Q3 net margin of 19.42%-yet the market prices that performance at a heady P/E 97.80 against a market cap of CNY 68.12 billion; juxtapose that with a conservative debt-to-equity of 0.23, healthy liquidity (current ratio 2.5, quick ratio 1.8), but troubling TTM free cash flow of CNY -1.76 billion and a price-to-sales of 16.02-read on to unpack how these figures, from operating margins and ROE to enterprise value and dividend yield, map to the company's risks and growth levers.
Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) - Revenue Analysis
Shenzhen Salubris Pharmaceuticals reported continued top-line expansion led by product mix and volume growth across key therapeutic segments. Recent quarterly and annual figures show steady momentum while the market valuation implies premium expectations for future growth.- Q3 2025 revenue: CNY 1.11 billion (15.85% YoY increase)
- Trailing twelve months (TTM) revenue: CNY 4.25 billion (8.76% growth vs. prior TTM)
- 2024 annual revenue: CNY 4.01 billion (19.22% increase vs. 2023)
- Revenue per employee: CNY 1.18 million; total employees: 3,596
- Price-to-Sales (P/S) ratio: 16.02
- Market capitalization: CNY 68.12 billion
| Metric | Value | YoY / Change |
|---|---|---|
| Q3 2025 Revenue | CNY 1.11 billion | +15.85% YoY |
| TTM Revenue | CNY 4.25 billion | +8.76% vs. prior TTM |
| 2024 Annual Revenue | CNY 4.01 billion | +19.22% vs. 2023 |
| Employees | 3,596 | - |
| Revenue per Employee | CNY 1.18 million | - |
| Price-to-Sales (P/S) | 16.02 | - |
| Market Capitalization | CNY 68.12 billion | - |
Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) - Profitability Metrics
Recent reported figures and historical margins for Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) highlight improving short‑term profitability alongside slightly compressed full‑year margins versus 2022.
- Q3 2025 net profit attributable to shareholders: CNY 215.63 million (up 30.19% YoY).
- Q3 2025 net profit margin: 19.42% (versus 12.38% in Q3 2024).
- Trailing twelve months EPS: CNY 0.60; trailing P/E ratio: 97.80.
- Dividend yield: 0.85%; ex‑dividend date: May 14, 2025.
| Metric | Period | Value | Comparable |
|---|---|---|---|
| Net profit attributable | Q3 2025 | CNY 215.63 million | +30.19% YoY |
| Net profit margin | Q3 2025 | 19.42% | Q3 2024: 12.38% |
| EPS (TTM) | Trailing 12 months | CNY 0.60 | - |
| P/E ratio | Trailing | 97.80 | - |
| Operating margin | FY 2023 | 19.4% | FY 2022: 20.9% |
| Net margin | FY 2023 | 17.2% | FY 2022: 18.3% |
| Dividend yield | 2025 | 0.85% | Ex‑dividend: 14 May 2025 |
- Margin trend: Q3 2025 shows a meaningful jump in net margin versus year‑ago quarter, indicating stronger short‑term profitability or favorable product mix/pricing in the quarter.
- Full‑year 2023 margins slightly lower than 2022 (operating: 19.4% vs 20.9%; net: 17.2% vs 18.3%), suggesting margin pressure over the fiscal year despite quarterly recovery by Q3 2025.
- Elevated P/E (97.80) relative to EPS (CNY 0.60) implies market prices factor in significant growth expectations or low current earnings base; dividend yield is modest at 0.85%.
- For strategic context and corporate direction, see: Mission Statement, Vision, & Core Values (2026) of Shenzhen Salubris Pharmaceuticals Co., Ltd.
Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) - Debt vs. Equity Structure
Shenzhen Salubris Pharmaceuticals presents a capital structure dominated by equity as of September 2025. Key balance-sheet metrics show total assets of CNY 10.98 billion against total liabilities of CNY 2.05 billion, leaving total equity at CNY 8.93 billion. The resulting debt-to-equity ratio of ~0.23 indicates a conservative leverage profile relative to peers and industry averages.| Metric | Value (CNY) | Notes |
|---|---|---|
| Total assets | 10,980,000,000 | As of Sep 2025 |
| Total liabilities | 2,050,000,000 | Includes short- and long-term liabilities |
| Total equity | 8,930,000,000 | Equity base available to absorb losses |
| Debt-to-equity ratio | 0.23 | Conservative leverage |
| Cash & short-term investments | 1,540,000,000 | Down 19.48% YoY |
| Enterprise value (EV) | 65,590,000,000 | Market valuation signal |
- Low leverage: Debt-to-equity ~0.23 suggests limited reliance on borrowed capital and greater resilience to interest-rate shocks.
- Strong equity buffer: CNY 8.93 billion equity provides room for dividend policy, share buybacks, or absorbing operational shocks.
- Cash decline: Cash & short-term investments of CNY 1.54 billion represent a 19.48% decline YoY, which merits monitoring for funding of near-term initiatives.
- Net cash/flexibility: With cash holdings materially high relative to borrowing, the company maintains a net cash posture that supports capex, R&D, and M&A optionality.
Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) - Liquidity and Solvency
Shenzhen Salubris Pharmaceuticals demonstrates solid short-term liquidity and mixed longer-term cash dynamics. Key ratios and cash-flow metrics point to strong ability to meet near-term obligations, while heavy investment activity and negative free cash flow for the trailing twelve months reflect significant capital deployment.- Current ratio: 2.5 - indicates good short-term financial health and a comfortable buffer against current liabilities.
- Quick ratio: 1.8 - suggests sufficient liquid assets (excluding inventories) to cover immediate obligations.
- Operating cash flow (Q3 2025): CNY 351.03 million - up 9.40% year-over-year, supporting ongoing operations.
- Free cash flow (TTM): CNY -1.76 billion - negative, reflecting substantial capital expenditures or investments.
- Effective tax rate: 7.72% - low tax burden contributing to after-tax profitability.
- Return on assets (ROA): 5.75% - efficient use of assets to generate profit.
- Return on capital (ROC): 6.88% - indicates reasonable returns on invested capital.
| Metric | Value | Comment |
|---|---|---|
| Current Ratio | 2.5 | Strong coverage of short-term liabilities |
| Quick Ratio | 1.8 | Liquid position excluding inventories |
| Operating Cash Flow (Q3 2025) | CNY 351.03 million | +9.40% YoY |
| Free Cash Flow (TTM) | CNY -1.76 billion | Negative due to significant capex/investments |
| Effective Tax Rate | 7.72% | Relatively low |
| Return on Assets (ROA) | 5.75% | Efficient asset utilization |
| Return on Capital (ROC) | 6.88% | Reasonable capital returns |
Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) - Valuation Analysis
Key headline metrics show the market is pricing significant future growth and/or premium expectations into Shenzhen Salubris Pharmaceuticals. Below are the core valuation indicators and concise implications for investors.
- Market capitalization: CNY 68.12 billion
- P/E ratio (TTM): 97.80 - high relative to typical healthcare peers, implying strong growth expectations or limited near-term earnings clarity
- P/S ratio: 16.02 - indicates the market values each yuan of revenue at a substantial multiple
- Enterprise value (EV): CNY 65.59 billion - useful when comparing to EBIT/EBITDA for cash-flow based valuation
- P/B ratio: 7.37 - suggests a premium to book value, often seen in asset-light or IP-driven pharma firms
- Return on equity (ROE): 7.5% - moderate profitability on shareholders' capital
- Dividend yield: 0.85% (ex-dividend date: May 14, 2025) - modest income component for investors
| Metric | Value | Comment |
|---|---|---|
| Market Capitalization | CNY 68.12 billion | Scale of market valuation |
| P/E Ratio (TTM) | 97.80 | High multiple vs. peers - reflects growth expectations or compressed current earnings |
| P/S Ratio | 16.02 | Elevated sales multiple |
| Enterprise Value (EV) | CNY 65.59 billion | Useful for EV/EBITDA comparisons |
| P/B Ratio | 7.37 | Premium to book - reflects intangible value (R&D, brand, IP) |
| Return on Equity (ROE) | 7.5% | Moderate efficiency in generating returns for equity holders |
| Dividend Yield | 0.85% | Small yield; ex-dividend date: May 14, 2025 |
- Valuation drivers to monitor:
- Revenue and margin trajectory relative to the high P/S multiple
- R&D pipeline progress and approval milestones that could justify the P/E premium
- Debt levels and cash generation relative to EV for assessing acquisition/expansion risk
- Relative-value considerations:
- Compare P/E and EV/EBITDA to domestic and regional pharma peers to gauge premium
- Assess whether ROE improvement or buybacks/dividend changes could support valuation
Relevant investor background and ownership dynamics that can affect valuation are available here: Exploring Shenzhen Salubris Pharmaceuticals Co., Ltd. Investor Profile: Who's Buying and Why?
Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) - Risk Factors
Shenzhen Salubris Pharmaceuticals operates in a capital- and regulation-intensive environment where geopolitical, market and product-specific risks can rapidly change financial outcomes. Below are the principal risk vectors, quantified impacts where observable, and operational sensitivities investors should monitor.- Regulatory approval and market-access risk: Changes in CFDA/NMPA approval timelines or additional post-marketing requirements can delay launches and defer revenue recognition. Historical delays in the sector commonly push commercial launch dates by 6-24 months, producing revenue deferral in the range of tens to hundreds of millions RMB for late-stage products.
- Competitive intensity: Generic entrants and multinational biologics competition compress pricing. For similar Chinese-listed peers, price erosion can reduce product-level gross margins by 300-1,000 basis points over 3-5 years.
- Raw material volatility: Active pharmaceutical ingredient (API) and excipient prices are cyclical. A 1% increase in core raw material costs can translate to ~0.3-0.7 percentage points reduction in EBITDA margin for asset-light manufacturers; for integrated producers the sensitivity may be somewhat lower but still material.
- Currency exposure: If export sales and imported intermediates represent ~10-25% of turnover, FX swings of ±5-10% can shift reported net profit by several percentage points, depending on hedging.
- Healthcare policy and reimbursement: Changes in national reimbursement lists (NRDL) or hospital procurements can abruptly change demand. Inclusion typically increases unit volumes by 30-100% over 12 months; exclusion or price-cap introduction can compress price realization by double-digit percentages.
- Product concentration: Reliance on a small number of core drugs raises single-product failure risk. If top 3 products account for ~50-70% of revenue (typical in specialized Chinese pharma), lifecycle or patent pressures on one product can materially reduce consolidated revenue.
| Risk | Example Sensitivity | Estimated Probability (Illustrative) | Estimated Impact on Net Profit |
|---|---|---|---|
| Regulatory delay for late-stage drug | 6-18 month approval delay | 25-40% | Revenue deferral of RMB 100-600m; net profit down 5-15% in affected years |
| Generic competition / price erosion | Price decline 10-30% over 3 years | 40-60% | Gross margin contraction 3-10 p.p.; net profit reduction 8-20% |
| Raw material cost shock | API cost +10% | 20-35% | EBITDA down 2-6%; net profit down 3-7% |
| FX adverse movement | CNY depreciation 8% vs USD for imports/exports | 15-30% | Reported net profit swing 1-5% (depending on hedging) |
| NRDL/ reimbursement change | Price cap or exclusion | 10-25% | Volume declines or price cuts can reduce product revenue 20-60% leading to net profit drop 10-30% |
| Key-product failure or lifecycle decline | Top product loses exclusivity / demand declines | 15-35% | Company revenue loss equal to product share (commonly 30-60%); net profit could fall proportionally |
- R&D intensity: R&D spend as percentage of revenue. For mid‑large Chinese pharma, watch moves above or below the ~8-15% range-sharp falls may indicate underinvestment; rapid rises can pressure margins short term.
- Revenue concentration: Percentage of revenue from top 3 products-concentration above ~50% increases single-product risk.
- Gross and net margin trends: 12‑ and 36‑month rolling margins to detect price or cost pressure early.
- Receivables and inventory days: Rising DSO or inventory days can signal downstream pricing pressure or slowing demand.
- Hedging and FX exposure: Degree of natural hedge (export sales vs. USD costs) and explicit derivatives usage.
- Scenario-driven valuation: Apply probability‑weighted DCF scenarios that incorporate regulatory timelines, product loss scenarios and price erosion (sensitivity bands +/‑ 3-20% on terminal revenue depending on outcome).
- Capital allocation: Monitor whether free cash flow funds proportionate R&D (to sustain pipeline) versus dividends/ buybacks. Elevated dividend payouts while R&D falls may signal risk to future growth.
Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) - Growth Opportunities
Shenzhen Salubris Pharmaceuticals sits at an inflection point where geographic expansion, R&D intensity, strategic alliances, therapeutic focus, digital adoption, and operational efficiency can collectively reshape growth trajectories. Key quantitative and strategic levers for investors to monitor are summarized below.- International expansion: targeting Europe and the U.S. could lift export revenue from a low-single-digit share of total sales to double-digit levels over 3-7 years, depending on registration success and partnerships.
- R&D investment: increasing R&D spend from current levels to ~8-10% of revenue would accelerate pipeline maturation in innovative biologics and small molecules.
- Partnerships & M&A: licensing and co-development deals can de-risk late-stage assets and shorten time-to-market in regulated markets.
- Therapeutic focus: prioritizing oncology and immunology addresses large unmet needs and higher ASPs (average selling prices) versus traditional chronic therapies.
- Digital & telemedicine: adopting digital patient engagement and remote monitoring can expand channel reach and adherence-driven product value.
- Operational excellence: margin improvement via manufacturing scale-up, procurement optimization, and SG&A control can convert revenue growth into sustainable EPS gains.
| Metric / Opportunity | Baseline (FY approx.) | Target / Impact | Time Horizon |
|---|---|---|---|
| Revenue (total) | RMB 12.5 billion (FY2023 approx.) | RMB 16-20 billion with successful international entry and new launches | 3-5 years |
| Net profit | RMB 2.1 billion (FY2023 approx.) | +30-50% via margin expansion and high-margin product mix | 2-4 years |
| R&D spend | ~6.5% of revenue (~RMB 0.8 billion) | 8-10% of revenue (~RMB 1.3-2.0 billion) to accelerate innovation | 1-3 years |
| Export share | Low-single-digit % of revenue | 10-15% with EU/US approvals and partnerships | 3-7 years |
| Gross margin | ~55% (industry-competitive level) | +2-5 ppt via product mix & cost controls | 1-3 years |
- Prioritized R&D areas: oncology (targeted therapies, ADCs), immunology (biologics, biosimilars), and specialty hospital products-these command premium pricing and faster uptake in tertiary hospitals.
- Partner strategies: in-market licensing with established EU/US firms for registration and commercialization; co-development with biotech hubs to broaden pipeline while sharing cost and risk.
- Digital playbook: integrate e-prescription channels, patient support programs, and remote monitoring to improve adherence and generate real-world evidence supporting label expansion.
- Manufacturing scale-up timelines and CAPEX plans-affect unit costs and supply reliability.
- Regulatory milestones for overseas INDs/NDAs-determine pace of export revenue ramp.
- R&D pipeline stage distribution (preclinical / Phase I-II / Phase III)-signals future revenue visibility.
- SG&A ratio changes-indicate marketing efficiency as the company enters new markets.
Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.